Beaver, Julia A.

FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC

Nakajima, E. C., Drezner, N., Li, X., Mishra-Kalyani, P. S., Liu, Y., Zhao, H., Bi, Y., Liu, J., Rahman, A., Wearne, E., et al. (2022) · Clinical Cancer Research

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 333

Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody

Maher, V. E., Fernandes, L. L., Weinstock, C., Tang, S., Agarwal, S., Brave, M., Ning, Y.-M., Singh, H., Suzman, D., Xu, J., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments

Cited by 331

FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors

Fallah, J., Brave, M. H., Weinstock, C., Mehta, G. U., Bradford, D., Gittleman, H., Bloomquist, E. W., Charlab, R., Hamed, S. S., Miller, C. P., et al. (2022) · Clinical Cancer Research

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 180

FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer

Shah, M., Osgood, C. L., Amatya, A. K., Fiero, M. H., Pierce, W. F., Nair, A., Herz, J., Robertson, K. J., Mixter, B. D., Tang, S., et al. (2022) · Clinical Cancer Research

Breast Cancer Treatment StudiesCancer Immunotherapy and Biomarkers

Cited by 105

U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer

Singh, H., Walker, A. J., Amiri-Kordestani, L., Cheng, J., Tang, S., Balcazar, P., Barnett-Ringgold, K., Palmby, T. R., Cao, X., Zheng, N., et al. (2018) · Clinical Cancer Research

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 99